NASDAQ:ENVB
Enveric Biosciences, Inc.
Enveric Biosciences, Inc. reported net income of −$8.8M in fiscal 2025. The diluted share count rose 698.7%.Summary generated from Enveric Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−304.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+698.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −65 | −27 | −16 | −10 | −9 |
| Net income | −49 | −18 | −17 | −10 | −9 |
| Free cash flow | −12 | −18 | −14 | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KOther events
Jun 9, 2026 - 8-KRegulation FD disclosure
Jun 9, 2026 - 4Insider transaction report
Jun 3, 2026 - 4Insider transaction report
Jun 3, 2026 - 8-KDirector or officer change
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026